
TNDM Stock Forecast & Price Target
TNDM Analyst Ratings
Bulls say
Tandem Diabetes Care is expected to see revenue growth in the next few years with their new product launch and transition to selling through pharmacies. This may initially decrease revenue but lead to higher profits in the long term, while moderate growth in new patients and potential for increased profitability through cost management make this company attractive. There are potential risks, such as competition and difficulty accessing the pharmacy channel, but overall, the company's positive outlook is reflected in analyst assessments.
Bears say
Tandem Diabetes Care is facing multiple challenges in the highly competitive diabetes device market. Its dependence on sales in the US, which contribute to a significant portion of its revenue, exposes the company to political and healthcare policy risks. The lower profitability margins and execution risks for its transition to the pharmacy channel also justify a discount in its current valuation. Despite potential growth opportunities from its product portfolio, there is limited confidence in Tandem's ability to execute and drive significant profit growth in the near future, resulting in a negative outlook on its stock.
This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.
TNDM Analyst Forecast & Price Prediction
Start investing in TNDM
Order type
Buy in
Order amount
Est. shares
0 shares